Q-omics provides the consensus-scored S100B profile across patient tissues and cancer cell-line models. S100B expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, S100B is differentially expressed in 14, with the highest sampling consensus in COAD. Additionally, S100B protein abundance shows 22,543 significant protein co-abundance associations, with the highest sampling consensus in HNSC. Together, these results highlight KIRP, COAD, and HNSC as cancer lineages where S100B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for S100B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes S100B survival associations across molecular data types. S100B RNA expression shows survival associations in the most cancer types (21), followed by mutation status (2) and mass-spec protein abundance (6). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible S100B RNA expression–survival associations across cancer types. High S100B expression shows unfavorable associations in KIRP and LGG, but favorable associations in UCEC, HNSC, CESC and SKCM. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for S100B RNA expression.
This table summarizes S100B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 5. The strongest signals are observed in COAD for RNA and COAD for protein.
This table ranks reproducible tumor–normal expression differences for S100B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. S100B shows lower tumor expression in COAD, KICH, BLCA, HNSC and BRCA and higher tumor expression in THCA. The COAD box plot shows higher S100B RNA expression in normal versus tumor tissue (log2 FC = −2.034, t-test p < 0.001).
This table shows molecular features associated with S100B in patient tissues and cancer cell lines. In patient samples, S100B shows the broadest associations at the RNA and protein expression levels, with HNSC recurring as the lineage with the largest associated feature set. In cancer cell lines, S100B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in SOFT_TISSUE, while CRISPR and shRNA rows add functional-dependency signals in BONE and SKIN.
